Yakup Ergün: Nivolumab/Relatlimab or Nivolumab/Ipilimumab in TNBC

Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared on X:

“Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in TNBC with high TILs: BELLINI trial

Stage I-II, node negative, TILs ≥50%, 30 patients

• pCR
• Nivo+IPI – 33%
• Nivo+RELA – 47%

Remarkable efficacy of chemotherapy-free immunotherapy for immunogenic TNBC”

Source: Yakup Ergün/X